Goodwin Advised Harbour BioMed On $175 Million Global Strategic Collaboration With AstraZeneca

Goodwin advised Harbour BioMed on $175 million global strategic collaboration with AstraZeneca

Goodwin Procter LLP advised Harbour BioMed on a strategic global collaboration agreement with AstraZeneca to discover and develop next-generation multi-specific antibodies for immunology, oncology, and other therapeutic areas.

The collaboration includes an initial payment, milestone payments, and option exercise fees totaling $175 million, with the potential for Harbour BioMed to receive up to $4.4 billion in additional development and commercial milestone payments. The deal also includes tiered royalties on future net sales and provides for the inclusion of additional programs over the next five years, with a further five-year extension option upon mutual agreement.

As part of this collaboration, AstraZeneca will have the option to license multiple programs utilizing Harbour BioMed’s proprietary Harbour Mice® fully human antibody technology platform. The initial focus will be on existing research programs, with future scope for expansion into additional therapeutic areas.

Harbour BioMed is a global biopharmaceutical company focused on novel antibody therapeutics in immunology and oncology, with a robust pipeline built through internal R&D, co-development partnerships, and strategic acquisitions.

The Goodwin team was led by Partner Zhenghui (Alan) Wang, with support from Christopher Zhong and Elliot Jonathan Horlick (IPTS); Arman Oruc (Antitrust/HSR); Susan Lee (FDA Regulatory); Daniel S. Karelitz and Katie Leah (Tax); Tim Worden and Beth Ashbridge (UK Corporate); Matt Wetzel (Healthcare Regulatory); Barry Z. Bazian (Bankruptcy); Catherine McCarty (Patent); and Alexandra D. Valenti (Litigation).

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.